Evidence map›Paper›PMID 37953374›Full record

ArticleVirchows Archiv : an international journal of pathology2023

Pseudoendocrine sarcoma: clinicopathologic, molecular, and epigenetic features of one case.

M Adelita Vizcaino, Andrew L Folpe, Henry Huffman, Ripul R Panchal, G Petur Nielsen, Benjamin R Kipp, Rust Turakulov, Kenneth Aldape, Caterina Giannini

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

M Adelita VizcainoDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Andrew L FolpeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Henry HuffmanAmeripath at Medical City, Plano, TX, USA.
Ripul R PanchalAmerican Neurospine Institute, Frisco, TX, USA.
G Petur NielsenDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Benjamin R KippDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Rust TurakulovLaboratory of Pathology, National Cancer Institute/Center for Cancer Research, Bethesda, MD, USA.
Kenneth AldapeLaboratory of Pathology, National Cancer Institute/Center for Cancer Research, Bethesda, MD, USA.
Caterina GianniniDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA. Giannini.Caterina@mayo.edu.
Mayo Clinic · USCenter for Cancer Research · USMassachusetts General Hospital · USMayo Clinic in Florida · USNeuroSpine Institute · US

Funding

Mayo Clinic IRB #21-9003
6 · The paper itself

Abstract

Pseudoendocrine sarcoma (PES) is a recently described neoplasm typically arising in paravertebral soft tissues. Histologically, PES resembles well-differentiated neuroendocrine tumors but lacks expression of epithelial/neuroendocrine markers, and most show aberrant nuclear β-catenin positivity. We describe the clinicopathological and molecular features and DNA methylation profile of one PES. A resected paraspinal soft tissue mass in a 52-year-old man showed a neuroendocrine-like neoplasm, negative for keratin, and synaptophysin and showing diffuse nuclear β-catenin expression. Targeted NGS confirmed a CTNNB1 (p.S37C) mutation. Whole genome methylation analysis showed no match to any methylation class in the central nervous system tumor (versions 11b6 and 12b6) or sarcoma classifier (calibrated scores of ≤0.3), but clustered together with a recently reported PES in which methylation analysis was also performed. He remained disease-free for 18 months after surgery, followed by chemoradiation. As more cases are examined, our findings suggest that PES may have a unique methylation profiling signature.

Indexed as

SarcomaSoft Tissue Neoplasmsbeta CateninBiomarkers, TumorEpigenesis, GeneticHumansMaleMiddle AgedMutationbeta CateninBiomarkers, TumorCTTNB1 mutationsNeuroendocrine-likePseudoendocrine sarcomaSoft tissueWhole-genome methylation profiling

Identifiers

PMID37953374
OpenAlexW4388616622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.